Genmab A (GMAB) Cash from Operations (2018 - 2026)
Genmab A's (GMAB) quarterly Cash from Operations came in at 3000000.0 in Q1 2026, down 98.95% YoY from 287000000.0 in Q1 2025, and down 99.66% on a QoQ basis from 885000000.0 in Q3 2025.
Genmab A (GMAB) Cash from Operations (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Cash from Operations data on file, last reported at 3000000.0 in Q1 2026.
- Quarterly Cash from Operations fell 98.95% year-over-year to 3000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1524000000.0 (down 9.34% YoY) and the FY2025 annual result came in at 1186000000.0, up 5.33% from the prior year.
- Cash from Operations declined to 3000000.0 in Q1 2026, from 885000000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 885000000.0 in Q3 2025 to a low of 3000000.0 in Q1 2026.
- A 3-year average of 416857142.86 and a median of 349000000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations jumped 31.05% — and 2026, when it slumped 98.95%.
- Tracing GMAB's Cash from Operations over 3 years: stood at 737000000.0 in 2024, then grew by 20.08% to 885000000.0 in 2025, then slumped by 99.66% to 3000000.0 in 2026.
- The last three Cash from Operations figures came in at 3000000.0 (Q1 2026), 885000000.0 (Q3 2025), and 349000000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 314.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.00 Mn |
| Jun 30, 2026 | 314.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Sep 30, 2025 | 885.00 Mn |
| Jun 30, 2025 | 349.00 Mn |
| Jun 30, 2025 | 349.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Mar 31, 2025 | 287.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Sep 30, 2024 | 737.00 Mn |
| Jun 30, 2024 | 438.00 Mn |
| Jun 30, 2024 | 438.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Mar 31, 2024 | 219.00 Mn |
| Sep 30, 2020 | 5,078.00 |
| Sep 30, 2020 | 5,078.00 |
| Dec 31, 2019 | 319.00 |
| Dec 31, 2019 | 319.00 |